Based on the CYP-Guides controlled RCT registered in ClinicalTrials.gov using identified NCT 02120729 (4), a standard treatment protocol was contrasted to a CYP2D6 genotype treatment for patients with major depressive disorder (MDD). This evidence concerns the gene CYP2D6 and major depressive disorder.